Opus Genetics to Present OPGx-BEST1 Cohort 1 Clinical Data in Investor Webcast and at Upcoming Leading Ophthalmology Conferences
Topline data from Phase 1/2 Cohort 1 of OPGx-BEST1 gene therapy program to be presented during investor conference call and webcast on September 9 at 8:00 a.m. ET
Full clinical dataset and additional analyses evaluating key measures of visual function to be presented at upcoming medical meetings
RESEARCH TRIANGLE PARK, N.C., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. ("Opus" or the "Company"), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced plans to present topline clinical data from Cohort 1 of its Phase 1/2 study of OPGx-BEST1 during an investor conference call and webcast on Wednesday, September 9, 2026, at 8:00 a.m. ET.
The Company also plans to present the full clinical dataset and additional analyses from the OPGx-BEST1 program at several upcoming medical conferences.
Investor Conference Call and Webcast
Opus Genetics will host an investor conference call and webcast on Wednesday, September 9, 2026, at 8:00 a.m. ET to present topline data from Cohort 1 of the Phase 1/2 clinical study of OPGx-BEST1.
Date:Wednesday, September 9, 2026
Time:8:00 a.m. ET
Webcast: Opus Genetics Investor Events
A live webcast and accompanying presentation will be available in the Investors section of the Company's website. A replay will be available following the event.
Upcoming Conference Presentations
Euretina Innovation Spotlight (EIS)
Date: Wednesday, September 30, 2026
Time: 14:20-14:56 CEST
Presenter: Ben Yerxa
Title: Advancing the Future of IRDs: Opus Genetics Clinical Development Update
Euretina 2026
Date: Sunday, October 4, 2026
Time: 13:15-13:21 CEST
Presenter: Mark Pennesi, M.D., Ph.D., Professor of Ophthalmology, School of Medicine, Casey Eye Institute, School of Medicine
Title: Initial Results from Cohort 1 of a Phase 1b/2a Clinical Study of OPGx-BEST1 Gene Therapy for the Treatment of BVMD and ARB Due to BEST1 Mutations
Retina in Rio
Date: Wednesday, October 14, 2026
Title: Structure-Function Correlation of EZ-RPE Thickness and MAIA Microperimetry in BEST1-Related Retinopathy: Results from the Phase 1/2 BIRD-1 Study of OPGx-BEST1 Gene Therapy
Presenter: George Magrath, M.D, CEO, Opus Genetics
Title: Near Normalization of Cone Sensitivity using Gene Augmentation in Children with LCA5
Presenter: Rodrigo Jorge, M.D., Ph.D., Head of Ophthalmology Department at University of São Paulo
FLORetina Presentation
Title: Phase 1/2 Cohort 1 3M Results of OPGx-BEST1 Gene Therapy in Patients with BVMD and ARB Due to BEST1 Mutations
Presenter: Aaron Nagiel, M.D., Ph.D.
About OPGx-BEST1
OPGx-BEST1 is an investigational gene therapy designed to address the underlying genetic cause of BEST1-related inherited retinal diseases, including BVMD and ARB. OPGx-BEST1 uses an AAV vector to deliver a functional copy of the BEST1 gene to retinal pigment epithelial cells. The ongoing BIRD-1 study is an adaptive, open-label Phase 1/2 clinical trial evaluating the safety and efficacy of single-eye subretinal administration of OPGx-BEST1 in adults with BVMD or ARB.
About Opus Genetics
Opus Genetics is a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs). The Company is developing durable, one-time treatments designed to address the underlying genetic causes of severe retinal disorders. The Company's pipeline includes seven AAV-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RDH12, MERTK, RHO, CNGB1 and NMNAT1. The Company is based in Research Triangle Park, NC. For more information, visit www.opusgtx.com .
Contacts
Investors
Jenny Kobin
Remy Bernarda
IR Advisory Solutions
ir@opusgtx.com
Media
Kimberly Ha
KKH Advisors
917-291-5744
kimberly.ha@kkhadvisors.com
